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Munich, GermanyAbstractThe water-soluble prodrug MCB3837 is rapidly converted to
MCB3681, active against Gram-positive bacterial species, after
intravenous infusion. The aim of this study was to prove the
principle that MCB3681 is efﬁcacious in vivo by demonstrating its
effect on the resident microﬂora or colonizers of the human skin,
nose, oropharynx and intestine. MCB3837 was infused at a daily
dose of 6 mg/kg for 5 days. MCB3681 was active against clostridia,
biﬁdobacteria, lactobacilli, enterococci and Staphylococcus aureus,
thus proving the principle that MCB3681 is antibacterially
efﬁcacious in vivo without affecting the Gram-negative microﬂora.
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This is an open access artiThe proof that an antibacterial agent may be clinically effective is
provided by studies in experimental animals and by pharmaco-
kinetic/pharmacodynamic (PK/PD) analysis [1–5] (Committee
for Proprietary Medicinal Products, http://www.ema.europa.eu/
docs/en_GB/document_library/Scientiﬁc_guideline/2009/09/
WC500003420.pdf; US Food and Drug Administration, http://
www.fda.gov/downloads/drugs/guidancecomplianceregulatory
information/guidances/ucm182288.pdf; European Medicines
Agency, http://www.ema.europa.eu/docs/en_GB/document_
library/Scientiﬁc_guideline/2010/03/WC500079928.pdf), fol-
lowed by phase 2 clinical studies. However, PK/PD targets cannot
always be derived for all antibacterial agents from studies in
experimental animals. The investigational agent MCB3837, a
small-molecule prodrug with structural elements of an oxazoli-
dinone and a quinolone being converted to the active substance
MCB3681, provides such an example [6]. Alternative strategies
thus had to be identiﬁed to prove the principle that MCB3681 is
antibacterially efﬁcacious in vivo. The evaluation of the effects of
an investigational agent on indicator organisms or colonizers of
the human residentmicroﬂora of healthy volunteersmay provide
an alternative to traditional proof-of-principle studies [6]. In
contrast to the well-established and validated evaluation of the
ecology of an antibacterial agent by describing ﬂuctuations of
mean viable counts of the human resident microﬂora within the
entire study population during the study period [7–9], the intra-
individual analysis of its effects on the population densities of
indicator organisms or colonizers of the commensal skin, nasal,
oropharyngeal and intestinal microﬂora, paralleled by an evalu-
ation of local drug concentrations as a proof of its in vivo efﬁcacy,
has so far not been applied.
Here we describe the effects of MCB3681 on the human
resident microﬂora or colonizers of healthy volunteers as a
proof of its in vivo efﬁcacy. These effects were investigated in
the context of a multiple-dose phase 1 study. Twelve healthy
male subjects received intravenous infusions of MCB3837 at
daily doses of 6 mg/kg body weight over 12 hours for 5 days.
Study design, PK and microbiologic sampling and speciﬁcation of
indicator organisms, sample processing and safety assessments
have been described in detail elsewhere [9]. Species-speciﬁc
intra-individual ﬂuctuations of viable counts over time were
analysed. Arithmetic means of viable counts (log10 colony-
forming units (CFU) per matrix, i.e. per milliliter of saliva, per
square centimetre of skin, per gram of faeces and per nostril)
were calculated per indicator organism and per sampling time
of those volunteers from whom bacteria could be cultivated at
preexposure on day −1 and/or on day 2 of drug exposure.
Viable counts below the limit of detection (i.e. <2 log10 CFU/
matrix) were calculated as 0. Viable counts of indicator or-
ganisms during exposure to MCB3681 (i.e. on days 2 and/or 5)Clin Microbiol Infect 2015; 21: 767.e1–767.e4
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TABLE 1. Time course of viable counts of indicator organisms isolated from faeces, nostrils, facial skin and saliva of volunteers before exposure (day −1), during exposure (days 2
and 5) and after exposure (days 8, 12 and 19) to MCB3681
Species
No. of
volunteers Matrix (log10 CFU/matrix) Day −1 Day 2 Day 5 Day 8 Day 12 Day 19
Day 2 minus
Day −1a
Day 5 minus
Day −1 or Day 2a log10
Day 2b Day 5b
Reduction (n) Increase (n) Reduction (n) Increase (n)
Clostridium spp. 8 Faeces (log10 CFU/g) 4.23 1.96 1.20 0.76 3.86 3.52 −2.28 −3.04 1 to <2 0 1 1 0
0.97 2.53 2.17 2.01 2.34 1.63 2.12 2.54 2 5 0 6 1
Lactobacillus spp. 11 Faeces (log10 CFU/g) 5.19 4.45 1.16 3.22 4.54 4.93 −0.75 −4.03 1 to <2 2 0 0 0
1.63 2.08 1.64 2.15 2.05 1.20 0.57 1.41 2 1 0 11 0
Biﬁdobacterium spp. 11 Faeces (log10 CFU/g) 7.94 5.86 0.00 1.34 2.95 5.24 −2.08 −7.94 1 to <2 2 0 0 0
0.80 2.99 0.00 2.29 3.92 3.98 3.20 0.80 2 3 0 11 0
Enterococcus spp. 9 Faeces (log10 CFU/g) 5.05 3.53 1.29 3.01 6.71 5.07 −1.51 −3.76 1 to <2 2 0 1 1
1.09 1.59 2.62 3.37 1.17 2.57 1.98 2.40 2 3 0 7 0
Bacteroides spp. 12 Faeces (log10 CFU/g) 8.95 8.64 8.43 8.72 8.43 8.73 −0.31 −0.52 1 to <2 0 0 1 0
0.39 0.68 0.58 0.49 0.96 0.84 0.74 0.70 2 1 0 1 0
Escherichia coli 12 Faeces (log10 CFU/g) 6.21 7.44 7.77 7.68 7.18 6.38 1.23 1.56 1 to <2 0 4 0 2
2.19 2.43 2.41 2.40 0.69 1.11 1.09 1.34 2 0 3 0 5
Staphylococcus aureus 7 Nostrils (log10 CFU/nostril) 5.09 4.33 2.73 3.10 3.00 2.87 −0.21 −1.69 1 to <2 1 0 1 1
n = 3 1.06 1.84 2.77 2.66 2.61 n = 3 2.30 2 0 0 2 0
S. aureus 4 Facial skin (log10 CFU/cm
2) 3.00 2.58 0.71 2.52 2.40 2.20 −1.50 −2.61 1 to <2 0 0 0 0
n = 2 1.58 1.23 1.52 1.41 1.44 n = 2 1.52 2 1 0 3 0
Lactobacillus spp. 7 Saliva (log10 CFU/mL) 3.87 4.16 3.84 4.16 3.93 3.70 0.29 −0.02 1 to <2 0 3 2 0
0.71 0.74 2.09 1.24 1.23 1.25 1.16 1.93 2 1 0 1 2
Lactobacillus spp. 3 Saliva, decreases only (log10 CFU/mL) 3.85 3.40 1.83 3.33 2.93 2.42 −0.45 −2.03 1 to <2 0 0 2 0
1.00 0.30 1.43 1.10 0.66 0.40 1.29 0.53 2 1 0 1 0
Arithmetic means of log10 CFU/matrix provided; italicized values represent standard deviations. Negative values indicate reduction and positive values, growth of indicator organisms.
CFU, colony-forming unit.
aDifferences between viable counts on days 2 and 5 of MCB3681 exposure, and on day −1 or day 2 if a preexposure value on day −1 was not available. Indicated is the number of volunteers from whom the corresponding species could be isolated
on day −1.
bNumber of volunteers with reductions and increases of viable counts of 1 to <2 log10 and 2 log10 CFU/matrix on days 2 and 5.
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CMI Dalhoff et al. Effects of MCB3681 767.e3were compared to both pre- and postexposure levels; in case
no growth was recorded in the preexposure sample, changes of
viable counts from day 2 to day 5 were analysed. A drug
exposure–related effect was deﬁned as a reduction of viable
counts of the nasal, oropharyngeal, skin and/or faecal microﬂora
by >2 log10 titres during drug exposure compared to pre- and
postexposure levels, representing proof of principle of the
antibacterial effect of MCB3681. A reduction of viable counts
by >1 and <2 log10 titres was considered to indicate a trend.
The study protocol was approved by the ethics committee of
Karolinska Institutet (Stockholm, Sweden) and the Medical
Products Agency (Uppsala, Sweden).
Marked effects of MCB3681 on the Gram-positive faecal ﬂora
were recorded during drug exposure (Table 1). Viable counts of
clostridia (Fig. 1) and lactobacilli were reduced fromday−1 to day
5 by 3.0 and 4.0 log10 CFU/g, respectively, and approximated
preexposure levels by days 12 or 19. Viable counts of biﬁdo-
bacteria were reduced below the limit of detection on day 5 and
approached preexposure levels by day 19 in two thirds of the
volunteers. Enterococci were reduced by 3.8 log10 CFU/g during
exposure and returned to preexposure levels thereafter. Viable
counts of Gram-negative faecal indicator organisms such as Bac-
teroides (Fig. 1) and Escherichia coliwere not affected by exposure
to MCB3681. Drug effects on other Enterobacteriaceae could
not be assessed as these species were isolated only occasionally.
Coagulase-negative staphylococci and Propionibacterium acnes
isolated from the nostrils were not affected by exposure to
MCB3681. However, viable counts of Staphylococcus aureus
isolated from the nostrils of seven volunteers were reduced by
1.7 log10 CFU/mL on day 5, and regrowth was observed in ﬁve
volunteers by day 19, while viable counts remained below the
limit of detection in two volunteers after exposure.FIG. 1. Individual time courses of viable
counts (log10 CFU/g) of Clostridium spp.
(n = 8; below dotted line) and Bacteroides
spp. (n = 12; above dotted line) isolated
from faeces of volunteers before expo-
sure (day −1), during exposure (day 5)
and after exposure (day 12) to MCB3681.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of E
This is an open access artiMCB3681 effects on P. acnes and coagulase-negative staph-
ylococci could not be evaluated because positive skin samples
were only occasionally obtained. However, S. aureus was iso-
lated from the facial skin of four volunteers, two on day −1 and
two on day 2. Viable counts were reduced in these four carriers
by 2.6 log10 CFU/cm
2 on day 5 and increased after exposure.
The oropharyngeal microﬂora was not affected by exposure
to MCB3681, except lactobacilli isolated from seven volunteers
before exposure. In three of them, viable counts were reduced
by 2.0 log10 CFU/mL during exposure and increased close to
preexposure levels in two volunteers.
Concentrations of MCB3681 were assessed in plasma, saliva
and faeces in the present study but not in nasal exudate and skin. A
previous microdialysis study demonstrated that MCB3681 pen-
etrates into subcutaneous tissue (T. Kapsner, personal commu-
nication), reﬂected by the effect of MCB3681 on skin-colonizing
S. aureus. Saliva concentrations were below the limit of detection,
mirrored by a marginal effect on the oropharyngeal ﬂora. High
faecal concentrations of MCB3681, ranging from 99 to 226mg/kg
faeces, translated into marked reductions of Gram-positive aer-
obic and anaerobic intestinal microﬂora during drug exposure.
Traditional PK/PD analyses cannot be applied for the
development of MCB3681. Therefore, alternative strategies
were identiﬁed to prove the principle that MCB3681 is anti-
bacterially efﬁcacious in vivo. In this study, a reduction of Gram-
positive indicator organisms or colonizers during drug expo-
sure compared to pre- and postexposure levels was observed
in the four habitats examined, proving that MCB3681 is efﬁ-
cacious in vivo against Gram-positive aerobic and anaerobic
bacterial species. The predeﬁned target for a proof of principle
(i.e. a reduction of population densities by >2 log10 titres) was
met for S. aureus, biﬁdobacteria, lactobacilli, enterococci and inuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 767.e1–767.e4
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
767.e4 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIparticular clostridia without affecting faecal E. coli and other
Enterobacteriaceae, as well as Bacteroides, considered impor-
tant for maintaining a healthy intestinal microbiome.
The marked effect of MCB3681 on clostridia, its high faecal
concentrations [9] and its high in vitro activity against Clostridium
difﬁcile [10] make MCB3681 an appealing candidate for clinical
development of intravenous treatment for C. difﬁcile infections.Transparency declarationThis study was funded by Morphochem Aktiengesellschaft für
kombinatorische Chemie (Munich, Germany). TK is an execu-
tive of Morphochem. All authors report no conﬂicts of interest
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